Inhibition on SHH pathway through targeting SMO has been reported by using two novel SMO inhibitors in MB, Sonidegib (NVP‐LDE225, LDE) and Vismodegib (GDC‐0449, GDC), which have been approved by FDA in basal cell carcinoma and being examined in MB in clinical trials.22, 23, 24, 25, 26, 27, 28. Here, SMO is linked to basal cell carcinoma.